Title: Menopause Research Act of 2022
Policy area: Health

Summary:
Menopause Research Act of 2022
This bill directs the National Institutes of Health to conduct or support research and related activities concerning menopause and the health of mid-life women. This includes evaluating past and current research and developing a strategic plan to guide future research.

[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[H.R. 8774 Introduced in House (IH)]

<DOC>






117th CONGRESS
  2d Session
                                H. R. 8774

To require the Director of the National Institutes of Health to conduct 
an evaluation of menopause-related research (including gaps in research 
   and knowledge regarding the causes, symptoms, and treatments for 
 menopause), to develop a strategic plan to resolve gaps in knowledge 
and research, and identify topics in need of further research relating 
 to potential treatments for menopause-related symptoms, and for other 
                               purposes.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                           September 6, 2022

Mr. McKinley (for himself and Mrs. Axne) introduced the following bill; 
       which was referred to the Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL


 
To require the Director of the National Institutes of Health to conduct 
an evaluation of menopause-related research (including gaps in research 
   and knowledge regarding the causes, symptoms, and treatments for 
 menopause), to develop a strategic plan to resolve gaps in knowledge 
and research, and identify topics in need of further research relating 
 to potential treatments for menopause-related symptoms, and for other 
                               purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Menopause Research Act of 2022''.

SEC. 2. EVALUATION OF MENOPAUSE-RELATED RESEARCH.

    (a) In General.--The Director of the National Institutes of Health 
shall--
            (1) conduct an evaluation of--
                    (A) the results of completed menopause-related 
                research, and research on mid-life women's health;
                    (B) the status of ongoing menopause-related 
                research, and research on mid-life women's health; and
                    (C) any gaps in knowledge and research on--
                            (i) treatments for menopause-related 
                        symptoms; and
                            (ii) the safety and effectiveness of 
                        treatments for menopause-related symptoms; and
            (2) as part of such evaluation, identify the total amount 
        of funding allocated by the National Institutes of Health for 
        the conduct or support of menopause-related research, and 
        research on mid-life women's health over the preceding 5 fiscal 
        years.
    (b) Report; Strategic Plan.--Not later than 180 days after the date 
of enactment of this Act, the Director of the National Institutes of 
Health shall submit to the Congress--
            (1) a report on the findings of such evaluation; and
            (2) a strategic plan--
                    (A) to resolve the gaps in knowledge and research 
                identified in the report; and
                    (B) to identify topics in need of further research 
                relating to potential treatments for menopause-related 
                symptoms.

SEC. 3. MENOPAUSE-RELATED RESEARCH, AND RESEARCH ON MID-LIFE WOMEN'S 
              HEALTH.

    (a) In General.--The Secretary of Health and Human Services, acting 
through the Director of the National Institutes of Health, shall 
conduct or support menopause-related research, and research on mid-life 
women's health.
    (b) Authorization of Appropriations.--There is authorized to be 
appropriated to carry out this section $100,000,000 for each of fiscal 
years 2023 and 2024.
                                 <all>